ALSO IN THIS MONTH'S ISSUE

• What To Expect From Cell Therapy And Gene Therapy In 2022 And Beyond

  From innovations in clinical development and manufacturing to the evaluation of investigational cell and gene therapies (CGTs), subject matter experts from Cellectis and Immatics share a brief look back on 2021 and a detailed glimpse into the near future of gene therapy and cell therapy respectively.

• Formulation Alternatives: Looking Beyond Parenteral Biologics

  2022 could be a breakout year for oral, intranasal, and inhalable biologics. As innovative biopharma companies clear formulation, stability, and efficacy hurdles, market forecasts are rising fast.

• Can the FDA & CDC Recover from Recent Politics?

  Five leading biopharma executives discuss the perils of political influence over the FDA and CDC and why every member of the industry should care.

• Is Janssen’s Pathway Approach The Future Of Drug Development

  Two Janssen execs talk about the future of what they call a pathway approach to developing new medicines, which attempts to match the biology of a pathway to unmet medical need for patients, across a broad range of immune-mediated, inflammatory disease.